Skip to main content
. 2021 Jun 25;11:702924. doi: 10.3389/fonc.2021.702924

Figure 3.

Figure 3

Comparison of ICIs efficacy between patients with and without brain metastases by subgroups. OS, overall survival; PFS, progression-free survival; ICIs, immune checkpoint inhibitors; CT, chemotherapy; HR, hazard ratio; CI, confidence interval.